Profile data is unavailable for this security.
About the company
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
- Revenue in USD (TTM)0.00
- Net income in USD-8.05m
- Incorporated2012
- Employees8.00
- LocationRenovoRx Inc333 W Santa Clara St Ste 900SAN JOSE 95113-1716United StatesUSA
- Phone+1 (408) 800-2649
- Fax+1 (302) 636-5454
- Websitehttps://renovorx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bolt Biotherapeutics Inc | 11.32m | -63.03m | 30.23m | 100.00 | -- | 0.2902 | -- | 2.67 | -1.66 | -1.66 | 0.2987 | 2.73 | 0.0649 | -- | -- | 113,240.00 | -36.11 | -48.32 | -39.88 | -54.03 | -- | -- | -556.59 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Surrozen Inc | 0.00 | -37.58m | 30.55m | 42.00 | -- | 0.6677 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Janone Inc | 0.00 | -18.58m | 30.70m | 5.00 | -- | -- | -- | -- | -3.66 | -3.95 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -69.38 | -23.12 | -88.46 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.1264 | -- | -- | -- | -313.15 | -- | -- | -- |
| Spruce Biosciences Inc | 10.13m | -46.75m | 30.86m | 22.00 | -- | 0.4633 | -- | 3.05 | -1.15 | -1.15 | 0.2483 | 1.62 | 0.0894 | -- | -- | 349,206.90 | -41.26 | -41.24 | -50.47 | -46.49 | -- | -- | -461.67 | -1,774.39 | -- | -114.54 | 0.0423 | -- | -- | -- | -3.77 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 31.69m | 40.00 | -- | 5.63 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 32.27m | 34.00 | -- | 20.44 | -- | 5.47 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Lipocine Inc | 4.71m | -8.97m | 32.30m | 17.00 | -- | 1.34 | -- | 6.86 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.05m | 32.81m | 8.00 | -- | 13.08 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Aspira Women's Health Inc | 9.15m | -16.69m | 33.12m | 64.00 | -- | -- | -- | 3.62 | -1.73 | -1.73 | 0.9683 | -0.2222 | 0.7746 | 14.34 | 6.77 | 143,031.30 | -141.23 | -110.58 | -256.99 | -151.88 | 57.48 | 45.23 | -182.32 | -334.08 | 0.9871 | -- | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Nuo Therapeutics Inc | 608.53k | -3.17m | 33.18m | -- | -- | 31.93 | -- | 54.53 | -0.0754 | -0.0754 | 0.0145 | 0.0235 | 0.2471 | 0.5609 | 3.55 | -- | -128.78 | -116.16 | -173.76 | -354.84 | 79.28 | 70.02 | -521.17 | -854.53 | 2.01 | -1,002.61 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.24m | -42.19m | 33.49m | 57.00 | -- | 0.5845 | -- | 14.96 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 34.98m | 6.00 | -- | 453.74 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -20.59m | 35.05m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 35.18m | 163.00 | -- | 0.1724 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to RenovoRx Inc's reporting currency: US Dollar USD
3.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nixon Peabody Trust Co. LLCas of 31 Mar 2024 | 97.17k | 0.91% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 56.74k | 0.53% |
| Geode Capital Management LLCas of 31 Dec 2023 | 55.76k | 0.52% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 49.23k | 0.46% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 20.84k | 0.20% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 18.85k | 0.18% |
| HRT Financial LLCas of 31 Dec 2023 | 14.04k | 0.13% |
| Affinity Capital Advisors LLCas of 31 Mar 2024 | 13.28k | 0.12% |
| Tower Research Capital LLCas of 31 Dec 2023 | 4.60k | 0.04% |
| BofA Securities, Inc.as of 31 Dec 2023 | 117.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
